Wave Life Sciences Inc WVE
NASDAQ · United States · Health Technology
$3.79-0.09 (-2.32%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.